ATTY. DOCKET NO. U. S DEPARTMENT OF COMMERCE SERIAL NO. ·FORM PTO-1449 PATENT AND TRADEMARK OFFICE U 014840-0 10/679,961 APPLICANT INFORMATION DISCLOSURE STATEMENT BY APPLICANT Robert SEEMAYER, et al. (Use several sheets if necessary) FILING DATE **GROUP** October 6, 2003 1625 U.S. PATENT DOCUMENTS DOCUMENT FILING DATE IF EXAMINER REFERENCE APPROPRIATE INITIALS DESIGNATION NUMBER DATE NAME 10/1992 LOWE, III AA5,162,339 AB OCT 2 7 2004
OFFICE OF PETITIONS ACAD AEAFAGΑH Αl ΑJ AK. FOREIGN PATENT DOCUMENTS **DOCUMENT** TRANSLATION NUMBER DATE COUNTRY YES NO AL AMAN AO ΑP

	0	THER ART (Including Author, Title, Date, Pertinent Dates, Etc.)
Br	AR	Seward, E. M., "Quinuclidine-Based NK-1 Antagonists 1: 3-Benzyloxy-1-Azabicyclo[2.2.2]Octanes", <i>Bioorganic & Medical Chemistry Letters</i> , Vol. 3, No. 6, pp. 1361-1366, 1993
	AS	\$
	AT	
EXAMINER/	AS UT	DATE CONSIDERED 12/6/1/

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.